Olympus KK
7733
ISIN JP3201200007 / Valor 763197
Olympus KK
UMushroom community rating:
About company
Olympus KK is a global medical technology company specializing in endoscopic and therapeutic solutions. The company leverages its expertise in medical technology, therapeutic intervention, and precision manufacturing to provide healthcare professionals with tools for diagnostic, therapeutic, and minimally invasive procedures. Olympus' Endoscopic Solutions portfolio includes endoscopes, laparoscopes, video imaging systems, and system integration solutions, while its Therapeutic Solutions portfolio features surgical energy devices and various instruments aimed at disease prevention, detection, and treatment. With a history dating back to the introduction of the first gastrocamera in 1950 and the development of the polypectomy snare, Olympus continues to innovate in order to improve clinical outcomes, reduce healthcare costs, and enhance patient safety and quality of life.
Summarized from source with an LLMView SourceSector: Consumer Non-CyclicalsLatest Results (17.12.2024):
Revenue Growth
Olympus KK reported a revenue of ¥936,210 million for the fiscal year ended March 31, 2024, marking a 6.2% increase from the previous fiscal year. This growth reflects the company's continued expansion and successful market strategies.
Operating Profit Decline
The operating profit for Olympus KK significantly decreased by 76.6% to ¥43,598 million in the fiscal year ended March 31, 2024. This decline indicates challenges in managing operational costs or other financial pressures during the period.
Profit Attributable to Owners
Profit attributable to owners of Olympus KK for the fiscal year ended March 31, 2024, was ¥316,425 million, showing a substantial increase of 60.9% compared to the previous year. This rise suggests improved profitability and effective financial management.
Dividend Increase
Olympus KK announced an annual dividend of ¥18.00 per share for the fiscal year ended March 31, 2024, up from ¥16.00 in the previous year. The company forecasts a further increase to ¥20.00 per share for the fiscal year ending March 31, 2025, reflecting confidence in future earnings.
Positive Financial Outlook
For the fiscal year ending March 31, 2025, Olympus KK forecasts a revenue of ¥1,021,000 million, representing a 9.1% increase. The company also anticipates a significant rise in operating profit by 306.0% to ¥177,000 million, indicating a strong positive outlook for the upcoming year.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
17873 M
Market cap (USD)
2,659,000
Daily traded volume (Shares)
2397.5 / 2361
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
J V
Laura Bischofberger
Lea Katunaric
EQUITIES OF THE SAME SECTOR
